Recurrent and fatal akinetic crisis in genetic‐mitochondrial parkinsonisms

Akinetic crisis (AC) is the most severe and possibly lethal complication of parkinsonism. It occurs with an incidence of 3‰ Parkinson's disease patients per year, but it is not known whether genetically determined parkinsonism is more or less susceptible to this complication.

[1]  A. Schapira,et al.  Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease , 2013, Cell metabolism.

[2]  John-Paul Taylor,et al.  Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies , 2013, Journal of Neurology.

[3]  A. Consiglio,et al.  Interplay of LRRK2 with chaperone-mediated autophagy , 2013, Nature Neuroscience.

[4]  Chunyan Wang,et al.  Leucine‐rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin‐like protein , 2012, Journal of neurochemistry.

[5]  M. Onofrj,et al.  Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies , 2010, Neurology.

[6]  B. Margetić,et al.  Neuroleptic malignant syndrome and its controversies , 2010, Pharmacoepidemiology and drug safety.

[7]  A. Singleton,et al.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.

[8]  M. Zeviani,et al.  Two novel POLG1 mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism , 2008, Neuromuscular Disorders.

[9]  M. Onofrj,et al.  Akinetic crisis, acute akinesia, neuroleptic malignant‐like syndrome, Parkinsonism–hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal , 2005, Movement disorders : official journal of the Movement Disorder Society.

[10]  C. Klein,et al.  Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes , 2005, Neurology.

[11]  M. Onofrj,et al.  Acute akinesia in Parkinson disease , 2005, Neurology.

[12]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[13]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[14]  I. Kanazawa,et al.  A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. , 2003, Parkinsonism & related disorders.

[15]  S. Tsuji,et al.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.

[16]  M Zappia,et al.  Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[17]  A. Terashi,et al.  Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease , 1999, Neurology.

[18]  H. Möller,et al.  Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics , 1997, Molecular and Cellular Biochemistry.

[19]  J. Kelly,et al.  Neuroleptic medications inhibit complex I of the electron transport chain , 1993, Annals of neurology.

[20]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.